AGARWALEYEDr. Agarwal's Health Care Ltd.
Dr. Agarwal's Health Care Q2 FY27 Results: Consolidated Net Profit ₹56.85 Crore on Total Income of ₹665 Crore
- Earnings
- eye care services
Reviewed byRachit TripathiBlacklitt Research
Dr. Agarwal's Health Care (NSE: AGARWALEYE) reported consolidated total income of ₹665.13 crore and net profit of ₹56.85 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. Standalone total income was ₹572.95 crore and standalone net profit ₹43.52 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹665.13 crore, up 31.3% YoY and 7.2% QoQ
- Net profit: ₹56.85 crore, up 55.8% YoY and 3.3% QoQ; ₹51.62 crore attributable to owners
- EPS: ₹1.65 basic, against ₹1.07 a year earlier; not annualised
- Finance costs: ₹23.00 crore, up 2.0% YoY and down 1.6% QoQ
Standalone
The company on its own, without its subsidiaries
- Total income: ₹572.95 crore, up 32.4% YoY and 7.9% QoQ
- Net profit: ₹43.52 crore, up 90.7% YoY and 8.7% QoQ
- EPS: ₹1.31 basic, against ₹0.70 a year earlier; not annualised
- Exceptional items: ₹0.72 crore, provision for impairment of loan to subsidiary
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 665.13 | 506.62 | +31.3% | 620.43 | +7.2% | |
| Revenue from operations | 655.46 | 498.69 | +31.4% | 614.02 | +6.7% |
| Other income | 9.67 | 7.93 | +21.9% | 6.41 | +50.9% |
| 56.85 | 36.49 | +55.8% | 55.02 | +3.3% | |
| Profit before tax | 79.89 | 53.66 | +48.9% | 75.14 | +6.3% |
| Finance costs | 23.00 | 22.55 | +2.0% | 23.37 | -1.6% |
| Depreciation | 82.67 | 67.86 | +21.8% | 78.31 | +5.6% |
| Tax expense | 23.04 | 17.17 | +34.2% | 20.12 | +14.5% |
| Net profit margin | 8.55% | 7.20% | +1.34 pp | 8.87% | -0.32 pp |
| EPS, basic (₹) | 1.65 | 1.07 | +54.2% | 1.55 | +6.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The filing gives no reason for the gap between consolidated net profit and profit attributable to owners, nor for the consolidated exceptional item; it is not known from the text read whether either will recur.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 572.95 | 432.84 | +32.4% | 530.76 | +7.9% | |
| Revenue from operations | 564.56 | 426.70 | +32.3% | 525.59 | +7.4% |
| Other income | 8.39 | 6.14 | +36.6% | 5.17 | +62.3% |
| 43.52 | 22.82 | +90.7% | 40.05 | +8.7% | |
| Profit before tax | 59.27 | 34.10 | +73.8% | 53.46 | +10.9% |
| Finance costs | 21.32 | 21.02 | +1.4% | 21.73 | -1.9% |
| Depreciation | 72.83 | 59.41 | +22.6% | 69.02 | +5.5% |
| Tax expense | 15.75 | 11.28 | +39.6% | 13.41 | +17.4% |
| Net profit margin | 7.60% | 5.27% | +2.32 pp | 7.55% | +0.05 pp |
| EPS, basic (₹) | 1.31 | 0.70 | +87.1% | 1.21 | +8.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 90.7% YoY to ₹43.52 crore, against total income growth of 32.4%, and grew faster than profit before tax of 73.8%. Standalone tax rose 39.6% to ₹15.75 crore, 26.6% of profit before tax of ₹59.27 crore.
Standalone other income of ₹8.39 crore is 14.2% of profit before tax, and finance costs of ₹21.32 crore are 3.7% of total income. Standalone exceptional items of ₹0.72 crore are a provision for impairment of a loan to a subsidiary, as the filing names it.
Consolidated net profit of ₹56.85 crore is ₹13.33 crore higher than standalone, and consolidated total income is ₹92.18 crore higher. Consolidated net profit grew more slowly than standalone net profit in the quarter, 55.8% against 90.7%.
Inference
The scheme of amalgamation with Dr.
The board has proposed Dr. Amar Agarwal's appointment as Executive Chairman (Whole-Time Director) for three years from 1 Nov 2026, subject to members' approval by postal ballot; the ballot date is not stated in the filing.
The filing does not say how the acquisition of the North India hospital group will be funded beyond the ₹56 crore consideration, or what its contribution to results will be.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.